STAT May 13, 2024
Ed Silverman

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online meetings, phone calls, and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So to give it a nudge in a better direction, we are firing up the coffee kettle to brew some cups of stimulation. Our choice today is honey almond. Please feel free to join us. Meanwhile, we have once again assembled a few items of interest for you. Best of luck on your journey today and, of course, do keep in touch. …

When it comes to a crucial controversy over pharmaceutical patents, the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder
FDA nominee pitches AI application review
Marty Makary, Often Wrong as Pandemic Critic, Is Poised To Lead the FDA He Railed Against
Project Optimus: The evolution of dose optimisation in oncology
Califf: Do right by AI and patients

Share This Article